论文部分内容阅读
目的:探讨TGF-β1和CD105表达在宫颈尖锐湿疣(candyloma acuminatum,CA)和宫颈癌(cervical carcinoma,CC)发生以及演进过程中的作用,评估CD105作为抗血管生成靶分子在治疗宫颈病变中的临床应用价值。方法:用免疫组织化学Envision二步法检测42例CA、50例CC、和20例正常宫颈黏膜中TGF-β1和CD105的表达,采用聚合酶链反应(PCR-荧光法)技术检测宫颈分泌物中人乳头瘤病毒(HPV)DNA。结果:宫颈正常黏膜、CA和CC中HPV DNA检出率分别为20%、100%和92%;TGF-β1表达率分别为30.0%、52.4%和62.0%,差别有统计学意义(P<0.05)。在宫颈CA和CC中,TGF-β1表达仅与CC分期有显著相关性(P<0.01)。CD105标记的微血管密度(MVD)在宫颈正常黏膜、CA和CC中存在显著性差异(P<0.01)。MVD在不同CA病变大小之间存在显著性差异(P<0.05),在不同CC分级和分期之间存在显著性差异(分别P<0.01,P<0.05)。在CA和CC中,TGF-β1表达与MVD存在显著相关性(P<0.05)。结论:TGF-β1/CD105通路调控的微血管生成在CA和CC发生以及演进过程中发挥重要作用,CD105可以作为较好的抗血管生成治疗的候选靶分子。
OBJECTIVE: To investigate the role of TGF-β1 and CD105 expression in the development and progression of cervical cancer (CC) and condyloma acuminatum (CA), and evaluate the role of CD105 as an anti-angiogenic target in the treatment of cervical lesions Clinical application value. Methods: The expressions of TGF-β1 and CD105 in 42 cases of CA, 50 cases of CC and 20 cases of normal cervical mucosa were detected by immunohistochemical Envision two-step method. The cervical secretions were detected by polymerase chain reaction (PCR-fluorescence) Human papillomavirus (HPV) DNA. Results: The positive rates of HPV DNA in normal mucosa, CA and CC were 20%, 100% and 92%, respectively. The positive rates of TGF-β1 were 30.0%, 52.4% and 62.0% respectively, with significant difference (P < 0.05). In cervical CA and CC, TGF-β1 expression was only correlated with CC staging (P <0.01). CD105 marked microvessel density (MVD) in cervical normal mucosa, CA and CC there is a significant difference (P <0.01). There was a significant difference in the size of MVD between different CA (P <0.05). There was significant difference between different CC grades and staging (P <0.01, P <0.05, respectively). In CA and CC, there was a significant correlation between TGF-β1 expression and MVD (P <0.05). CONCLUSION: The angiogenesis mediated by TGF-β1 / CD105 pathway plays an important role in the development and progression of CA and CC. CD105 may serve as a candidate target for better anti-angiogenic therapy.